Vaxcyte is a clinical-stage biotechnology company developing a new generation of vaccines to address some of the most important and deadly infectious diseases worldwide. The company's cell-free protein synthesis platform, comprising the XpressCFTM platform, is capable of rapidly generating protein antigens that can be used in vaccines to protect against bacterial and viral pathogens. Vaxcyte's lead vaccine candidate, VAX-24, is a preclinical, 24-valent pneumococcal conjugate vaccine (PCV) being developed for the prevention of pneumococcal disease. The company is also developing VAX-XP, a PCV with expanded serotype coverage, as well as vaccines for Group A Streptococcus, Group B Streptococcus, and Lyme disease.